It is now ten years ago that ipilimumab, a monoclonal antibody that interrupts the binding between cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and B7, was shown to unleash T-cell activity, improving the overall survival of patients with metastatic melanoma [7]. This evidence concerns the gene CTLA4 and metastatic melanoma.